WO2004022760A1 - Generation of recombinant influenza virus using baculovirus delivery vector - Google Patents

Generation of recombinant influenza virus using baculovirus delivery vector Download PDF

Info

Publication number
WO2004022760A1
WO2004022760A1 PCT/EP2003/009375 EP0309375W WO2004022760A1 WO 2004022760 A1 WO2004022760 A1 WO 2004022760A1 EP 0309375 W EP0309375 W EP 0309375W WO 2004022760 A1 WO2004022760 A1 WO 2004022760A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
baculovirus
influenza
modified
virus
Prior art date
Application number
PCT/EP2003/009375
Other languages
French (fr)
Inventor
Reingard Grabherr
Andrej Egorov
Kanokwan Poomputsa
Wolfgang Ernst
Christian Kittel
Hermann Katinger
Original Assignee
Polymun Scientific Immunbiologische Forschung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polymun Scientific Immunbiologische Forschung Gmbh filed Critical Polymun Scientific Immunbiologische Forschung Gmbh
Priority to AU2003270099A priority Critical patent/AU2003270099A1/en
Priority to EP03750434A priority patent/EP1534845A1/en
Publication of WO2004022760A1 publication Critical patent/WO2004022760A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the present invention is in the fields of recombinant gene technology and vaccine development and relates to a method for rescuing recombinant viruses, particularly recombinant orthomyxoviruses, using baculovirus as a gene shuttle for delivery of desired viral genes to a mammalian host cell for expression. It further relates to a modified baculovirus genome as used in said method, and further to the manufacture of vaccines using said method for rescuing recombinant viruses.
  • influenza virus One of the most important and best characterized members of the orthomyxoviruses is influenza virus.
  • the genome of influenza virus is single stranded RNA of negative polarity that comprises approximately 13500 nucleotides.
  • the genome of both influenza A and B viruses is distributed into eight different segments, coding for nine structural proteins and two non-structural proteins (NS1, NS2) with regulatory functions.
  • the first 12 nucleotides at the 3' end and the first 13 nucleotides at the 5' end of each genome segment of influenza A viruses are conserved in all eight segments. Due to the segmented nature of the viral genome genetic reassortment takes place when mixed infection of two different influenza strains occurs (i.e. avian influenza A strains can reassort with human influenza A viruses).
  • RNP ribonucleoprotein complex
  • PB1, PB2, PA the three viral polymerase proteins
  • NP nuclear protein
  • Reverse genetics for negative-strand viruses first developed for influenza A virus by Luytjes et al (3), has significantly contributed to our biological understanding of these pathogens and still gives rise to improving the methods of vaccine development.
  • the manipulation of the influenza genome by reverse genetics has led to the possibility of preparing stable laboratory strains which contain site-directed mutations that can be designed in a way such that they confer attenuation in one or more genes.
  • establishment of NS gene engineering methods for influenza A virus allowed to discover the main function of the NS1 protein as interferon antagonist and permitted obtaining genetically stable attenuated strains thatcan be used as a live influenza vaccine (4, 5).
  • Baculovirus as Gene Delivery Tool Current methods of expressing genes in a mammalian cell include the use of viral vectors, such as those which are derived from retroviruses, adenoviruses, herpes viruses, vaccinia viruses, polio viruses, Sindbis viruses, or adeno-associated viruses.
  • Other methods of expressing an exogenous gene in a mammalian cell include direct injection of DNA, the use of ligand-DNA conjugates, the use of adenovirus-ligand- DNA conjugates, calcium phosphate precipitation, and methods which utilize a liposome- or polycation-DNA complex.
  • viruses of the family Baculoviridae have been used to express exogenous genes in insect cells and mammalian cells.
  • Baculoviridaes viruses of the family Baculoviridae (commonly referred to as baculoviruses) have been used to express exogenous genes in insect cells and mammalian cells.
  • One of the most studied baculoviruses is the Autographa californica multiple nuclear polyhedrosis virus (AcMNPV).
  • AcMNPV Autographa californica multiple nuclear polyhedrosis virus
  • the transduction of mammalian cells by baculovirus particles bears no safety risk for either product or operator.
  • the expression of the exogenous genes is transient, unless a G418-resistance-gene is included and selected for by the addition of G418.
  • the transient expression of a mammalian expression cassette present on the baculovirus genome is gene dosage-dependent, corresponding to the number of virus particles used in
  • the invention relates to the construction of one or more baculovirus clones that are able to express one or more, optionally all, genes necessary for the rescue of infectious influenza virus.
  • the baculovirus is a nuclear polyhedrosis virus and most preferably is AcMNPV.
  • Baculoviruses possess several advantages that make them an attractive method for influenza genetic manipulation. Multiple genes and large inserts (up to 38 kb) can be introduced into the baculovirus genome so that one or more or even all influenza genes can be delivered to Vero cells at once.
  • the baculoviruses are inherently unable to replicate in mammalian cells and are therefore considered biologically safe for therapeutic applications for humans.
  • baculovirus Autographa calif ornica nuclear polyhedrosis virus (AcNPV) is an insect virus with a large double- stranded circular DNA genome.
  • AcNPV baculovirus Autographa calif ornica nuclear polyhedrosis virus
  • baculoviruses have primarily been used to over-express proteins from insect derived host cells, they have been demonstrated to serve as a powerful vector to carry various genes into a variety of mammalian cell types at high frequencies (8).
  • baculovirus as an influenza gene delivery vector. Recombinant baculovirus harboring a truncated influenza A NS gene, resulting in a 38 amino acid long NS1 protein, was constructed.
  • GFP green fluorescent protein
  • subsequent infection of baculovirus-transduced Vero cells with a temperature-sensitive (ts) influenza helper virus whose NS gene segment was found to be responsible for the ts phenotype, and subsequent passages in Vero cells at 40 °C resulted in the isolation of an influenza virus carrying the baculovirus-derived truncated NS1 gene.
  • This virus designated ⁇ NS38, did not grow on Madin-Darby canine kidney (MDCK) cells or in eggs, but gave almost equal titers, compared to the wild type variant, in interferon deficient Vero cells (4).
  • the invention further relates to a baculovirus genome that contains one or more uni- or bidirectional expression cassettes encoding at least one natural or modified gene or gene segment or a combination of a least one natural and at least one modified gene or gene segment, of an orthomyxo virus.
  • the invention relates to Baculovirus genome wherein said at least one natural or modified gene or gene segment is from influenza A or B virus.
  • the invention relates to a baculovirus genome wherein said at least one natural or modified gene or gene segment encodes viral mRNA or viral genomic RNA, or both viral mRNA and viral genomic RNA.
  • the invention relates to a baculovirus genome wherein said at least one natural or modified gene or gene segment is flanked by restriction sites that allow for introduction and exchange of said gene or gene segment by cleavage of said restriction sites and subsequent direct ligation of said gene(s) or gene segment(s) into the baculovirus genome. These restriction sites are unique in baculovirus.
  • the invention relates to a baculovirus genome wherein said at least one natural or modified gene or gene segment comprises a modified NS gene segment of influenza virus encoding an NS1 protein of only 38 amino acids in length ( ⁇ NS38), wherein the 38 amino acids are the N-terminal starting sequence of the NS1 protein.
  • the big C-terminal truncation of the NS1 amino acid sequence renders the influenza virus interferon inducing and, simultaneously, interferon sensitive, which has in effect that the resulting virus is attenuated (at least due to its susceptibility to IFN activity) and thus a promising candidate for making live vaccines.
  • the invention relates to a baculovirus genome wherein said at least one natural or modified gene or gene segment comprises a modified NS gene segment of influenza virus, a hemagglutinin (HA) and/or a neuraminidase (NA) gene segment of an epidemic influenza strain, and all remaining gene segments of the epidemic strain or of one or more other influenza wildtype or laboratory master strains.
  • said at least one natural or modified gene or gene segment comprises a modified NS gene segment of influenza virus, a hemagglutinin (HA) and/or a neuraminidase (NA) gene segment of an epidemic influenza strain, and all remaining gene segments of the epidemic strain or of one or more other influenza wildtype or laboratory master strains.
  • the AcMNPV genome comprises 134 kbp of double-stranded DNA.
  • the capacity of foreign gene insertion into the baculovirus genome has been demonstrated to be at least 40 kbp of DNA. Therefore, it becomes possible to stably integrate more than one gene-expression cassette into the AcNPV genome, e.g. target gene plus reporter gene, protein complexes consisting of multiple subunits.
  • the baculovirus genome can carry an exogenous promoter positioned for expression of the exogenous gene.
  • Preferred promoters include the cytomegalovirus early promoter (CMV) and the human ribosomal RNA polymerase I promoter (Pol-I).
  • the baculovirus genome may also carry a polyadenylation signal, the bovine growth hormone poly adenylation signal (BGH-Poly A) or the hepatitis delta virus genomic ribozyme (HDN), a self-cleaving R ⁇ A sequence which ensures the correct 3 ' end.
  • BGH-Poly A bovine growth hormone poly adenylation signal
  • HDN hepatitis delta virus genomic ribozyme
  • the baculovirus is engineered to contain as a heterologous insertion into its genome at least one", preferably several, optionally all genes or gene segments of influenza virus, or of any other orthomyxovirus.
  • Influenza A as well as B viruses possess a segmented single-stranded, negative-strand R ⁇ A genome.
  • All R ⁇ A-segments must be produced as negative strand viral genomic R ⁇ A (vR ⁇ A) and four of these R ⁇ A segments must be present either as functional proteins or as transcripts encoding proteins that have to be functional for transcription and replication of all segments.
  • the different Orthomyxovirus genes may be engineered in any combination or number into a single baculovirus genome or may be divided into two or more portions and distributed to two or more separate baculovirus genomes.
  • a baculovirus containing just one foreign gene e.g. a modified version of the ⁇ S1 gene, may be used for transduction of Nero cells and rescue of infectious virus, e.g. influenza virus or any orthomyxovirus, may be carried out via superinfection with helper virus.
  • co- transduction of several baculoviruses, each 1 containg one or more different orthomyxovirus genes, may be carried out in order to rescue infectious orthomyxovirus particles, preferably without the aid of helper virus.
  • transduction refers to carrier-mediated transfer of genetic material to a living host cell, wherein the carrier is an enveloped virus and the genetic material is contained within the capsid of said virus, and wherein the transfer is accomplished in a way such that upon contact of the virus with the host cell the capsid containing the genetic material penetrates the host cell and migrates to the host cell's nucleus, while the viral envelope remains outside the host cell.
  • the baculovirus used according to the present invention is such a viral carrier.
  • transfection refers to the transfer, usually carrier-mediated transfer, of naked RNA or DNA, e.g. plasmid RNA or DNA vector constructs, to host cells.
  • Suitable carriers are, for instance, RNP (ribonucleoprotein complex) or lipids (e.g. Lipofectin ® ).
  • infection refers to the exposure of host cells to natural or modified viruses and the subsequent delivery of viral RNA or DNA to the host cell using natural pathways, including, as the case may be, penetration of the host cell by the whole virus.
  • the term applies to the delivery of influenza virus RNA gene segments to a host cell, e.g. a Nero cell, using an influenza wildtype or helper virus.
  • a baculovirus-delivered, truncated NS1 gene from influenza A virus ( ⁇ NS38-gene) was expressed in Vero cells and transcribed vRNA was successfully incorporated into influenza virus particles.
  • RT-PCR with PR8 and helper virus-specific primers was performed after plaque purification (Fig. 2).
  • a mixture of the truncated ⁇ NS38-vRNA and helper virus NS-vRNA was detected after two selective passages at 40°C. After several plaque purification steps, a homogenous virus population could be isolated and the ⁇ NS38 gene was confirmed by nucleotide sequence analysis.
  • Recombinant ⁇ NS38 virus showed similar growth patterns in interferon-deficient Vero cells as compared to the 25 A- 1 helper virus (a reassortant virus containing the NS segment form the cold-adapted influenza strain A/Leningrad/134/47/57 and the remaining genes from influenza A/PR/8/34) but was fully restricted from growth on MDCK cells or in eggs.
  • the baculovirus was shown for its effective delivery of foreign genes into Vero cells. Transduction efficiency of the recombinant baculovirus at different MOIs into Vero cells was evaluated, using GFP as a reporter gene. FACS analysis revealed that the Vero cell transduction was concentration-dependent (FIG.2B). More than 90% of the cells were transduced when recombinant baculovirus was used at MOI 5000, as evidenced by their expression of GFP 24 to 48 hours after transduction. Although high numbers of baculovirus particles may be required, this method is considered feasible and significantly superior to the afore-mentioned methods known in the art, since baculoviruses can be easily generated and grown to high titers in insect cells.
  • the truncated NS1 protein of this virus consisting of only 38 N-terminal amino acids, is responsible for the attenuated phenotype in mice, which is based on the finding that ⁇ NS38 virus has an interferon inducing but also an interferon sensitive phenotype.
  • some or all genes of the desired recombinant Orthomyxovirus are inserted into the genome of a single baculovirus and thereafter transduced into Vero cells for expression of the viral genes and for assembly and release of the desired recombinant Orthomyxoviruses.
  • some or all of the genes or gene segments, respectively, of the desired recombinant virus are divided into two portions and distributed into the genomes of two baculoviruses and thereafter co-transduced into Vero cells for expression and assembly of recombinant virus.
  • the term "desired” virus shall mean any virus having a pre-selected phenotype, preferably having an attenuated (e.g. temperature-sensitive, interferon-sensitive, or otherwise replication-inhibited) phenotype, and/or a pre-selected set of genes or gene segments.
  • the desired virus be an influenza virus that comprises a modified NS gene segment responsible for interferon induction and/or for interferon sensitivity such as the ⁇ NS38 gene segment (coding for a full NEP and a truncated NS1 protein of only 38 amino acids length), a hemagglutinin (HA) and/or a neuraminidase (NA) gene segment of an epidemic influenza virus strain, and some or all of the remaining gene segments of one or more other influenza wildtype or laboratory master strains.
  • a modified NS gene segment responsible for interferon induction and/or for interferon sensitivity such as the ⁇ NS38 gene segment (coding for a full NEP and a truncated NS1 protein of only 38 amino acids length), a hemagglutinin (HA) and/or a neuraminidase (NA) gene segment of an epidemic influenza virus strain, and some or all of the remaining gene segments of one or more other influenza wildtype or laboratory master strains.
  • HA hemag
  • the present invention also encompasses an embodiment, wherein a part or the entirety of genes or gene segments, respectively, of a desired recombinant virus, are split into more than two portions and distributed to more than two baculovirus genomes, each baculovirus genome receiving just one of said more than two portions of genes or gene segments, respectively.
  • the recombinant baculoviruses produced by this method and differing from one another by the inserted portion of foreign genes or gene segments are then co-transduced to the host cells, preferably Vero cells, for expression of the viral genes and assembly and release of the desired recombinant virus particles. Both methods have in common that they do not require the use of a helper virus to rescue the desired recombinant virus.
  • helper viruses wherein the transduced genes or gene segments replace the corresponding genes or gene segments of the helper virus.
  • this method requires the employment of a helper virus and a suitable subsequent selection system for rescuing the desired recombinant reassorted viruses (i.e. the modified helper viruses), it is still more efficient than all other reverse genetic methods known to us so far.
  • Fig. 1 Construction of recombinant NS expressing cassette.
  • the NS gene was cloned in reverse orientation between human polymerase I promoter (Poll) and hepatitis delta virus terminator (HDV) to transcribed NS vRNA.
  • a multiple stop codon cassette was introduced, resulting in a truncated, 38 amino acid NS1 protein and a full size, 121 aa NEP.
  • the non- translated part between the stop codon and the splicing signal of NEP was deleted.
  • Fig. 2 Expression of the reporter gene (GFP) in infected Vero cells depending upon baculovirus concentration.
  • GFP reporter gene
  • Vero cells were transduced with baculovirus carrying a GFP reporter gene at different MOIs. Using FACS analysis, the percentage of GFP expressing cells was measured (i.e. reflecting cells are transduced with baculovirus).
  • Fig. 3 Detection of the recombinant influenza NS gene.
  • Virus-containing supernatant obtained from Vero cell culture after transduction with baculovirus and subsequent infection with influenza helper virus, was passaged twice at 40°C and analyzed by RT-PCR, using two sets of primers which selectively detect only wild-type (lane 1) or only recombinant, truncated gene (lane 2)
  • the supernatant comprises a mixture of helper virus 25 A- 1 and rescued ⁇ NS38 virus (Fig. 3 A).
  • Fig. 3B After several plaque purification steps a pure recombinant ⁇ NS38 virus was isolated (Fig. 3B).
  • Influenza virus 25 A- 1 is a temperature-sensitive (ts) reassortant containing the NS gene from the cold-adapted strain A/Leningrad/134/47/57 (H2N2) and the remaining genes from the A/Puerto Rico/8/34 (H1N1) virus.
  • the NS gene is responsible for the temperature-sensitive phenotype of the helper virus.
  • the virus was amplified in Vero cells in serum free medium.
  • the NS gene was cloned between human ribosomal polymerase I promoter (Poll) and hepatitis delta virus genomic ribozyme (HDV), a self-cleaving RNA sequence which ensures the correct 3' end.
  • a multiple stop codon cassette was introduced after the nuclear localization signal 1 (NLS1) of the NS1 protein.
  • the non-translated part between this stop codon cassette and the splicing signal of the nuclear export protein (NEP) was deleted and resulted in a truncated NS1 protein, consisting of only 38 amino acids but a fully intact NEP protein (6).
  • the NS construct, designated ⁇ NS38 was inserted into a baculovirus transfer vector (pCMVGFP), a modified pBacPA (Clonetech), expressing the green fluorescence protein (GFP) under control of the cytomegalovirus promoter (CMV) and the bovine growth hormone polyadenylation site (BGH) as reporter-gene.
  • pCMVGFP- ⁇ NS38 a baculovirus transfer vector
  • CMV cytomegalovirus promoter
  • BGH bovine growth hormone polyadenylation site
  • the recombinant plasmid (pCMVGFP- ⁇ NS38) and linear AcNPY viral DNA (Baculogold, PharMingen) were co-transfected into Spodoptera frugiperda (S ⁇ ) insect cells and recombinant AcCMVGFP- ⁇ NS38 baculoviruses were generated.
  • the recombinant AcCMVGFP- ⁇ NS38 baculoviruses were purified by
  • Vero cells were transduced with recombinant AcCMVGFP- ⁇ NS38 baculovirus, carrying a GFP reporter gene at different MOIs using the procedure described above. After 48 hours, the transduced cells were trypsinized and resuspended in PBS. GFP expressing cells were analyzed by a fluorescence activated cell sorter (FACS).
  • FACS fluorescence activated cell sorter
  • Influenza B virus genes of strain B Lee 40 were released from the cloning vector backbone pHW2000 by restriction digests and inserted into the baculovirus transfer vector pBacPAK ⁇ . More particularly, the three polymerase genes and the gene encoding the nuclear protein of influenza B virus (B Lee 40), were taken from the constructs pHW-Lee-PBl, pHW-Lee-PB2, pHW-Lee-PA, pHW-Lee-NP, which are based on pHW2000 (Hoffmann et al, 2000), kindly received from Thorsten Wolff (Robert Koch-Institute, Berlin) and were inserted each into a baculovirus transfer vector pBacPAK8 (Clontech).
  • the genes are expressed bidirectionally, transcription (i.e. generation) of the messenger RNA is driven by the cytomegalovirus (CMV) early promoter and terminated by the bovine growth hormone (BGH) polyadenylation signal. Transcription (i.e. generation) of genomic RNA is driven by the human polymerase I (Pol I) promoter and terminated by the hepatitis delta virus (HDV) genomic ribozyme, a self-cleaving RNA sequence to ensure the correct 3' end (Neuman et al., 1994). This set of proteins is required for reverse transcription of influenza virus genes and genes that are flanked by influenza virus non-coding sequences, where the nuclear complex binds and initiates transcription.
  • CMV cytomegalovirus
  • BGH bovine growth hormone
  • HDV hepatitis delta virus
  • Recombinant baculovirus clones were generated via homologous recombination using the above described transfer vectors, and amplified and purified by sucrose gradient centrifugation.
  • a plasmid was constructed, which contained the green fluorescent protein (gfp) in minus sense orientation, flanked by influenza B virus non-coding sequences.
  • the gene encoding minus sense RNA of green fluorescent protein is expressed under control of the human polymerase I promoter (Poll) and terminated by the hepatitis delta virus genomic ribozyme (HDV).
  • the RNP-complex comprising the four influenza B virus proteins (PA, PBl, PB2, NP) binds to the non-coding region and initiates transcription. Only when all four influenza virus proteins comprised in the nuclear complex (PBl, PB2, NP, PA) are functionally active hence successfully delivered and expressed, gfp mRNA is being produced and gfp expression can be detected by a fluorescent signal.
  • HEK293 Freestyle cells Invitrogen were transduced with a pool of the four baculovirus clones, using a total moi of either 50, 500, 1000, 5000 or 7500.
  • cells 48 hours post transduction, cells were transfected with 1 ⁇ g of purified plasmid containing the minus sense gfp gene flanked by influenza B virus non-coding sequences. Analysis was performed 24 hours post transfection by fluorescence activated cell sorting.
  • gfp was functionally expressed in the HEK293 freestyle cells due to transcriptional activity of the influenza B virus nuclear complex which formed and assembled within the cells upon delivery and expression of the four different baculovirus clones.
  • the principle underlying the present invention as claimed herein was fully confirmed. Particularly, it was proven that the present invention allows not only for successful delivery of several different genes of interest to a mammalian host cell using the baculovirus-based transduction system but also for successful expression of the delivered genes.
  • each clone comprising another influenza virus gene or gene segment can likewise result in successful transcription and expression of the delivered genes and subsequent assembly of the expressed proteins to form virus particles.
  • RNA polymerase I mediates expression of influenza virual RNA molecules. Virology, 202, 477-479.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to a method wherein a baculovirus delivery system is used as an alternative for the rescue of recombinant influenza virus. A recombinant baculovirus vector containing mammalian cell-active promoters and transcription terminators was used for delivery of the influenza NS gene segment to Vero cells. In addition to the influenza NS gene segment, the recombinant baculovirus vector contained a reporter gene expression cassette (GFP), allowing to monitor the Vero cell transduction efficiency. More than 90 percent of Vero cells were expressing GFP 24 to 48 hours after transduction. After infecting baculovirus-transduced cells with influenza helper virus, recombinant influenza progeny carrying the synthetic, baculovirus-derived NS gene was isolated. The method further relates to the chimeric baculovirus and to its chimeric genome and further to a method of manufacture of recombinant influenza vaccines using the baculovirus transduction method.

Description

Generation of recombinant influenza virus using Baculovirus delivery vector
TECHNICAL FIELD
The present invention is in the fields of recombinant gene technology and vaccine development and relates to a method for rescuing recombinant viruses, particularly recombinant orthomyxoviruses, using baculovirus as a gene shuttle for delivery of desired viral genes to a mammalian host cell for expression. It further relates to a modified baculovirus genome as used in said method, and further to the manufacture of vaccines using said method for rescuing recombinant viruses.
BACKGROUND OF THE INVENTION
One of the most important and best characterized members of the orthomyxoviruses is influenza virus. The genome of influenza virus is single stranded RNA of negative polarity that comprises approximately 13500 nucleotides. The genome of both influenza A and B viruses is distributed into eight different segments, coding for nine structural proteins and two non-structural proteins (NS1, NS2) with regulatory functions. The first 12 nucleotides at the 3' end and the first 13 nucleotides at the 5' end of each genome segment of influenza A viruses are conserved in all eight segments. Due to the segmented nature of the viral genome genetic reassortment takes place when mixed infection of two different influenza strains occurs (i.e. avian influenza A strains can reassort with human influenza A viruses). Several reverse-genetic systems have been developed to allow manipulation of the viral genome. One system is based on the principle that synthetic influenza vRNA was transcribed in vitro and encapsulated with the ribonucleoprotein complex (RNP), consisting of the three viral polymerase proteins (PB1, PB2, PA) and the nuclear protein (NP). Infection with influenza helper virus of RNP transfected cells provides the remaining viral proteins and RNA segments. Using a strong selection system it was possible to isolate virus progeny carrying the recombinant gene (1, 2).
Reverse Genetics
Reverse genetics for negative-strand viruses, first developed for influenza A virus by Luytjes et al (3), has significantly contributed to our biological understanding of these pathogens and still gives rise to improving the methods of vaccine development. The manipulation of the influenza genome by reverse genetics has led to the possibility of preparing stable laboratory strains which contain site-directed mutations that can be designed in a way such that they confer attenuation in one or more genes. For example, establishment of NS gene engineering methods for influenza A virus allowed to discover the main function of the NS1 protein as interferon antagonist and permitted obtaining genetically stable attenuated strains thatcan be used as a live influenza vaccine (4, 5).
Plasmid-Based Technology
Recently a new plasmid-based technology has been developed for rescuing recombinant influenza A viruses. Co-transfection of 8 to 18 plasmids in a mixture expressing all influenza genomic fragments and proteins required for their transcription allowed to obtain infectious influenza A viruses in the absence of any natural helper strains (6, 7). The advantage of this strategy is that selection for reassortants is no longer required, since only the genes of interest are being expressed.
However, one obvious disadvantage of this system is the necessity to use many plasmids for transfection and the low probability of their simultaneous appearance in a transfected cell. As the genetically modified genes can only be introduced by plasmid delivery, transfection efficiency plays a major role in a successful rescue of recombinant influenza virus progeny. In addition, according to our knowledge, only few cell lines can effectively be used in such transfection protocols.
Baculovirus as Gene Delivery Tool Current methods of expressing genes in a mammalian cell include the use of viral vectors, such as those which are derived from retroviruses, adenoviruses, herpes viruses, vaccinia viruses, polio viruses, sindbis viruses, or adeno-associated viruses. Other methods of expressing an exogenous gene in a mammalian cell include direct injection of DNA, the use of ligand-DNA conjugates, the use of adenovirus-ligand- DNA conjugates, calcium phosphate precipitation, and methods which utilize a liposome- or polycation-DNA complex. Also, viruses of the family Baculoviridae (commonly referred to as baculoviruses) have been used to express exogenous genes in insect cells and mammalian cells. One of the most studied baculoviruses is the Autographa californica multiple nuclear polyhedrosis virus (AcMNPV). The transduction of mammalian cells by baculovirus particles bears no safety risk for either product or operator. The expression of the exogenous genes is transient, unless a G418-resistance-gene is included and selected for by the addition of G418. The transient expression of a mammalian expression cassette present on the baculovirus genome is gene dosage-dependent, corresponding to the number of virus particles used in the experiment. While the transport efficiency of naked plasmid DNA to the nucleus is dependent on the sequence and structural features of the plasmid and therefore less reproducible within different gene constructs, the entire baculovirus capsid containing the target genes gets efficiently and essentially without alterations tranferred into the nucleus, independently of the genetic structure of the contained gene constructs.
BRIEF DESCRIPTION OF THE INVENTION
The invention relates to the construction of one or more baculovirus clones that are able to express one or more, optionally all, genes necessary for the rescue of infectious influenza virus. It is preferred that the baculovirus is a nuclear polyhedrosis virus and most preferably is AcMNPV. Baculoviruses possess several advantages that make them an attractive method for influenza genetic manipulation. Multiple genes and large inserts (up to 38 kb) can be introduced into the baculovirus genome so that one or more or even all influenza genes can be delivered to Vero cells at once. The baculoviruses are inherently unable to replicate in mammalian cells and are therefore considered biologically safe for therapeutic applications for humans. According to the present invention, a more simple, highly efficient alternative method using baculovirus as a delivery vehicle was developed. The baculovirus Autographa calif ornica nuclear polyhedrosis virus (AcNPV) is an insect virus with a large double- stranded circular DNA genome. Although baculoviruses have primarily been used to over-express proteins from insect derived host cells, they have been demonstrated to serve as a powerful vector to carry various genes into a variety of mammalian cell types at high frequencies (8). We investigated the use of baculovirus as an influenza gene delivery vector. Recombinant baculovirus harboring a truncated influenza A NS gene, resulting in a 38 amino acid long NS1 protein, was constructed. This truncation of NS1 mediates an irreversible attenuation of influenza A virus (4) and is considered to be a valuable tool for safe influenza vaccine development. Further, green fluorescent protein (GFP) was used as a reporter gene and included into the baculovirus genome. The efficiency of baculovirus-based transduction of Vero cells with influenza genes was monitored by GFP expression.
In one embodiment, subsequent infection of baculovirus-transduced Vero cells with a temperature-sensitive (ts) influenza helper virus, whose NS gene segment was found to be responsible for the ts phenotype, and subsequent passages in Vero cells at 40 °C resulted in the isolation of an influenza virus carrying the baculovirus-derived truncated NS1 gene. This virus, designated ΔNS38, did not grow on Madin-Darby canine kidney (MDCK) cells or in eggs, but gave almost equal titers, compared to the wild type variant, in interferon deficient Vero cells (4).
The invention further relates to a baculovirus genome that contains one or more uni- or bidirectional expression cassettes encoding at least one natural or modified gene or gene segment or a combination of a least one natural and at least one modified gene or gene segment, of an orthomyxo virus. In a preferred embodiment the invention relates to Baculovirus genome wherein said at least one natural or modified gene or gene segment is from influenza A or B virus.
In yet another emodiment, the invention relates to a baculovirus genome wherein said at least one natural or modified gene or gene segment encodes viral mRNA or viral genomic RNA, or both viral mRNA and viral genomic RNA. In yet another emodiment, the invention relates to a baculovirus genome wherein said at least one natural or modified gene or gene segment is flanked by restriction sites that allow for introduction and exchange of said gene or gene segment by cleavage of said restriction sites and subsequent direct ligation of said gene(s) or gene segment(s) into the baculovirus genome. These restriction sites are unique in baculovirus. In yet another emodiment, the invention relates to a baculovirus genome wherein said at least one natural or modified gene or gene segment comprises a modified NS gene segment of influenza virus encoding an NS1 protein of only 38 amino acids in length (ΔNS38), wherein the 38 amino acids are the N-terminal starting sequence of the NS1 protein. The big C-terminal truncation of the NS1 amino acid sequence renders the influenza virus interferon inducing and, simultaneously, interferon sensitive, which has in effect that the resulting virus is attenuated (at least due to its susceptibility to IFN activity) and thus a promising candidate for making live vaccines. In yet another emodiment, the invention relates to a baculovirus genome wherein said at least one natural or modified gene or gene segment comprises a modified NS gene segment of influenza virus, a hemagglutinin (HA) and/or a neuraminidase (NA) gene segment of an epidemic influenza strain, and all remaining gene segments of the epidemic strain or of one or more other influenza wildtype or laboratory master strains.
DETAILED DESCRIPTION OF THE INVENTION
The AcMNPV genome comprises 134 kbp of double-stranded DNA. The capacity of foreign gene insertion into the baculovirus genome has been demonstrated to be at least 40 kbp of DNA. Therefore, it becomes possible to stably integrate more than one gene-expression cassette into the AcNPV genome, e.g. target gene plus reporter gene, protein complexes consisting of multiple subunits. The baculovirus genome can carry an exogenous promoter positioned for expression of the exogenous gene. Preferred promoters include the cytomegalovirus early promoter (CMV) and the human ribosomal RNA polymerase I promoter (Pol-I). The baculovirus genome may also carry a polyadenylation signal, the bovine growth hormone poly adenylation signal (BGH-Poly A) or the hepatitis delta virus genomic ribozyme (HDN), a self-cleaving RΝA sequence which ensures the correct 3 ' end.
According to the present invention, the baculovirus is engineered to contain as a heterologous insertion into its genome at least one", preferably several, optionally all genes or gene segments of influenza virus, or of any other orthomyxovirus. Influenza A as well as B viruses possess a segmented single-stranded, negative-strand RΝA genome. For Orthomyxovirus replication and infection, all RΝA-segments must be produced as negative strand viral genomic RΝA (vRΝA) and four of these RΝA segments must be present either as functional proteins or as transcripts encoding proteins that have to be functional for transcription and replication of all segments. According to the present invention, the different Orthomyxovirus genes may be engineered in any combination or number into a single baculovirus genome or may be divided into two or more portions and distributed to two or more separate baculovirus genomes. A baculovirus containing just one foreign gene, e.g. a modified version of the ΝS1 gene, may be used for transduction of Nero cells and rescue of infectious virus, e.g. influenza virus or any orthomyxovirus, may be carried out via superinfection with helper virus. Alternatively and as a preferred embodiment, co- transduction of several baculoviruses, each1 containg one or more different orthomyxovirus genes, may be carried out in order to rescue infectious orthomyxovirus particles, preferably without the aid of helper virus.
The term "transduction" as used herein refers to carrier-mediated transfer of genetic material to a living host cell, wherein the carrier is an enveloped virus and the genetic material is contained within the capsid of said virus, and wherein the transfer is accomplished in a way such that upon contact of the virus with the host cell the capsid containing the genetic material penetrates the host cell and migrates to the host cell's nucleus, while the viral envelope remains outside the host cell. The baculovirus used according to the present invention is such a viral carrier.
The term "transfection" as used herein refers to the transfer, usually carrier-mediated transfer, of naked RNA or DNA, e.g. plasmid RNA or DNA vector constructs, to host cells. Suitable carriers are, for instance, RNP (ribonucleoprotein complex) or lipids (e.g. Lipofectin®).
The term "infection" as used herein refers to the exposure of host cells to natural or modified viruses and the subsequent delivery of viral RNA or DNA to the host cell using natural pathways, including, as the case may be, penetration of the host cell by the whole virus. For example, the term applies to the delivery of influenza virus RNA gene segments to a host cell, e.g. a Nero cell, using an influenza wildtype or helper virus.
Transduction efficiency of Vero cells by Baculovirus. The efficiency of recombinant baculovirus for gene transfer into Nero cells was investigated. Recombinant AcCMNGFP-ΔΝS38 baculoviruses carrying GFP reporter gene at different MOIs in the presence of DEAE dextran sulfate were transduced into the Nero cells. After 48 hours, GFP expressing cells were analysed by FACS analysis. Transduction of Nero cells by the recombinant AcCMVGFP-ΔΝS38 baculovirus was concentration-dependent as shown in FIG.2A. MOIs tested were 5, 50, 500 and 5000, yielding transfection rates of 2%, 9%, 62% and 91% respectively. No changes in cell viability and no cytopathic effects of transduced Vero cells were observed. Rescue of recombinant ΔNS38 influenza virus.
A baculovirus-delivered, truncated NS1 gene from influenza A virus (ΔNS38-gene) was expressed in Vero cells and transcribed vRNA was successfully incorporated into influenza virus particles. To analyze the viral progeny after selection, RT-PCR with PR8 and helper virus-specific primers was performed after plaque purification (Fig. 2). A mixture of the truncated ΔNS38-vRNA and helper virus NS-vRNA was detected after two selective passages at 40°C. After several plaque purification steps, a homogenous virus population could be isolated and the ΔNS38 gene was confirmed by nucleotide sequence analysis.
Growth ofΔNS38 virus in tissue culture.
Recombinant ΔNS38 virus showed similar growth patterns in interferon-deficient Vero cells as compared to the 25 A- 1 helper virus (a reassortant virus containing the NS segment form the cold-adapted influenza strain A/Leningrad/134/47/57 and the remaining genes from influenza A/PR/8/34) but was fully restricted from growth on MDCK cells or in eggs.
The baculovirus was shown for its effective delivery of foreign genes into Vero cells. Transduction efficiency of the recombinant baculovirus at different MOIs into Vero cells was evaluated, using GFP as a reporter gene. FACS analysis revealed that the Vero cell transduction was concentration-dependent (FIG.2B). More than 90% of the cells were transduced when recombinant baculovirus was used at MOI 5000, as evidenced by their expression of GFP 24 to 48 hours after transduction. Although high numbers of baculovirus particles may be required, this method is considered feasible and significantly superior to the afore-mentioned methods known in the art, since baculoviruses can be easily generated and grown to high titers in insect cells. We were able to demonstrate the efficient delivery of recombinant, truncated NS genes into influenza virus using baculovirus as a delivery vehicle. The truncated NS1 protein of this virus, consisting of only 38 N-terminal amino acids, is responsible for the attenuated phenotype in mice, which is based on the finding that ΔNS38 virus has an interferon inducing but also an interferon sensitive phenotype. Using the method of the present invention for the rescue of attenuated epidemic viruses, particularly influenza viruses, appears to be a promising way to obtain candidates for a live influenza vaccine and for the rapid and efficient manufacture of attenuated live vaccines.
In a preferred embodiment of the invention, some or all genes of the desired recombinant Orthomyxovirus, e.g. of a desired attenuated and/or recombinant influenza virus, are inserted into the genome of a single baculovirus and thereafter transduced into Vero cells for expression of the viral genes and for assembly and release of the desired recombinant Orthomyxoviruses. Alternatively and equally preferred from a technical point of view, some or all of the genes or gene segments, respectively, of the desired recombinant virus are divided into two portions and distributed into the genomes of two baculoviruses and thereafter co-transduced into Vero cells for expression and assembly of recombinant virus. The term "desired" virus shall mean any virus having a pre-selected phenotype, preferably having an attenuated (e.g. temperature-sensitive, interferon-sensitive, or otherwise replication-inhibited) phenotype, and/or a pre-selected set of genes or gene segments. For instance, it is preferred that the desired virus be an influenza virus that comprises a modified NS gene segment responsible for interferon induction and/or for interferon sensitivity such as the ΔNS38 gene segment (coding for a full NEP and a truncated NS1 protein of only 38 amino acids length), a hemagglutinin (HA) and/or a neuraminidase (NA) gene segment of an epidemic influenza virus strain, and some or all of the remaining gene segments of one or more other influenza wildtype or laboratory master strains. The present invention also encompasses an embodiment, wherein a part or the entirety of genes or gene segments, respectively, of a desired recombinant virus, are split into more than two portions and distributed to more than two baculovirus genomes, each baculovirus genome receiving just one of said more than two portions of genes or gene segments, respectively. The recombinant baculoviruses produced by this method and differing from one another by the inserted portion of foreign genes or gene segments are then co-transduced to the host cells, preferably Vero cells, for expression of the viral genes and assembly and release of the desired recombinant virus particles. Both methods have in common that they do not require the use of a helper virus to rescue the desired recombinant virus.
Where it is preferred to transduce just some of the viral genes of a desired recombinant virus into the host cell expression system, e.g. into Vero cells, it will be required to supply the remaining viral genes by other methods, for instance by infecting the transduced host cells with a helper virus. In doing so, some of the newly generated virions will be modified helper viruses, i.e. helper viruses wherein the transduced genes or gene segments replace the corresponding genes or gene segments of the helper virus. Although this method requires the employment of a helper virus and a suitable subsequent selection system for rescuing the desired recombinant reassorted viruses (i.e. the modified helper viruses), it is still more efficient than all other reverse genetic methods known to us so far.
BRIEF DESCRIPTION OF THE FIGURES
Fig. 1. Construction of recombinant NS expressing cassette. The NS gene was cloned in reverse orientation between human polymerase I promoter (Poll) and hepatitis delta virus terminator (HDV) to transcribed NS vRNA. At nucleotide position 140, a multiple stop codon cassette was introduced, resulting in a truncated, 38 amino acid NS1 protein and a full size, 121 aa NEP. The non- translated part between the stop codon and the splicing signal of NEP was deleted. Fig. 2: Expression of the reporter gene (GFP) in infected Vero cells depending upon baculovirus concentration. A) Vero cells were transduced with baculovirus carrying a GFP reporter gene at different MOIs. Using FACS analysis, the percentage of GFP expressing cells was measured (i.e. reflecting cells are transduced with baculovirus). B) Vero cells expressing GFP after 48 hours transduction with recombinant AcCMVGFP-ΔNS38 baculovirus. Fig. 3: Detection of the recombinant influenza NS gene.
Virus-containing supernatant, obtained from Vero cell culture after transduction with baculovirus and subsequent infection with influenza helper virus, was passaged twice at 40°C and analyzed by RT-PCR, using two sets of primers which selectively detect only wild-type (lane 1) or only recombinant, truncated gene (lane 2) In picture A, the supernatant comprises a mixture of helper virus 25 A- 1 and rescued ΔNS38 virus (Fig. 3 A). After several plaque purification steps a pure recombinant ΔNS38 virus was isolated (Fig. 3B).
Example 1.
Cell culture.
Spodoptera frugiperda (Sf9) insect cells were grown in IPL-41 insect medium
(Sigma- Aldrich Chemical) containing yeastolate and a lipid/sterol cocktail with 3% FCS at 27°C. Vero (WHO-certified) cells were grown in DMEM/Ham's F12
(Biochrom) protein free medium.
Influenza virus.
Influenza virus 25 A- 1 is a temperature-sensitive (ts) reassortant containing the NS gene from the cold-adapted strain A/Leningrad/134/47/57 (H2N2) and the remaining genes from the A/Puerto Rico/8/34 (H1N1) virus. The NS gene is responsible for the temperature-sensitive phenotype of the helper virus. The virus was amplified in Vero cells in serum free medium.
Construction of recombinant AcCMVGFP-ΔNS38 baculovirus.
The NS gene was cloned between human ribosomal polymerase I promoter (Poll) and hepatitis delta virus genomic ribozyme (HDV), a self-cleaving RNA sequence which ensures the correct 3' end. A multiple stop codon cassette was introduced after the nuclear localization signal 1 (NLS1) of the NS1 protein. The non-translated part between this stop codon cassette and the splicing signal of the nuclear export protein (NEP) was deleted and resulted in a truncated NS1 protein, consisting of only 38 amino acids but a fully intact NEP protein (6). The NS construct, designated ΔNS38 was inserted into a baculovirus transfer vector (pCMVGFP), a modified pBacPA (Clonetech), expressing the green fluorescence protein (GFP) under control of the cytomegalovirus promoter (CMV) and the bovine growth hormone polyadenylation site (BGH) as reporter-gene. The recombinant plasmid (pCMVGFP-ΔNS38) and linear AcNPY viral DNA (Baculogold, PharMingen) were co-transfected into Spodoptera frugiperda (Sβ) insect cells and recombinant AcCMVGFP-ΔNS38 baculoviruses were generated. The recombinant AcCMVGFP-ΔNS38 baculoviruses were purified by ultracentrifugation and resuspended in serum-free Vero cell medium.
Generation of recombinant ANS38 influenza viruses. Recombinant baculovirus inoculum (MOI=1000) with DEAE-dextran (1 :100) was added to Vero cells and incubated for two hours, followed by replacement of the inoculum with serum-free medium. After 24 hours, the baculovirus-transduced cells were infected with 25 A- 1 influenza helper viruses at MOI of 1 for 30 minutes. The helper virus inoculum was replaced with serum-free medium and the Vero cells were further incubated at 37°C for 24 h. The viral supernatant was passaged twice in Vero cells at 40°C and analyzed by RT-PCR followed by nucleotide sequence analysis for the presence of the ΔNS38. Following three rounds of plaque purification on Vero cells, recombinant influenza viruses containing the ΔNS38-vRNA were isolated (Fig. 3). Transduction efficiency of baculovirus in Vero cells.
Vero cells were transduced with recombinant AcCMVGFP-ΔNS38 baculovirus, carrying a GFP reporter gene at different MOIs using the procedure described above. After 48 hours, the transduced cells were trypsinized and resuspended in PBS. GFP expressing cells were analyzed by a fluorescence activated cell sorter (FACS).
Example 2.
Simultaneous co-transduction of four different gene segments.
Influenza B virus genes of strain B Lee 40 were released from the cloning vector backbone pHW2000 by restriction digests and inserted into the baculovirus transfer vector pBacPAKδ. More particularly, the three polymerase genes and the gene encoding the nuclear protein of influenza B virus (B Lee 40), were taken from the constructs pHW-Lee-PBl, pHW-Lee-PB2, pHW-Lee-PA, pHW-Lee-NP, which are based on pHW2000 (Hoffmann et al, 2000), kindly received from Thorsten Wolff (Robert Koch-Institute, Berlin) and were inserted each into a baculovirus transfer vector pBacPAK8 (Clontech). In these expression vectors, the genes are expressed bidirectionally, transcription (i.e. generation) of the messenger RNA is driven by the cytomegalovirus (CMV) early promoter and terminated by the bovine growth hormone (BGH) polyadenylation signal. Transcription (i.e. generation) of genomic RNA is driven by the human polymerase I (Pol I) promoter and terminated by the hepatitis delta virus (HDV) genomic ribozyme, a self-cleaving RNA sequence to ensure the correct 3' end (Neuman et al., 1994). This set of proteins is required for reverse transcription of influenza virus genes and genes that are flanked by influenza virus non-coding sequences, where the nuclear complex binds and initiates transcription.
Recombinant baculovirus clones were generated via homologous recombination using the above described transfer vectors, and amplified and purified by sucrose gradient centrifugation. In order to prove funcionality of the cloned genes, a plasmid was constructed, which contained the green fluorescent protein (gfp) in minus sense orientation, flanked by influenza B virus non-coding sequences. The gene encoding minus sense RNA of green fluorescent protein is expressed under control of the human polymerase I promoter (Poll) and terminated by the hepatitis delta virus genomic ribozyme (HDV).
The RNP-complex comprising the four influenza B virus proteins (PA, PBl, PB2, NP) binds to the non-coding region and initiates transcription. Only when all four influenza virus proteins comprised in the nuclear complex (PBl, PB2, NP, PA) are functionally active hence successfully delivered and expressed, gfp mRNA is being produced and gfp expression can be detected by a fluorescent signal. For this purpose, HEK293 Freestyle cells (Invitrogen) were transduced with a pool of the four baculovirus clones, using a total moi of either 50, 500, 1000, 5000 or 7500. 48 hours post transduction, cells were transfected with 1 μg of purified plasmid containing the minus sense gfp gene flanked by influenza B virus non-coding sequences. Analysis was performed 24 hours post transfection by fluorescence activated cell sorting.
It could be shown that gfp was functionally expressed in the HEK293 freestyle cells due to transcriptional activity of the influenza B virus nuclear complex which formed and assembled within the cells upon delivery and expression of the four different baculovirus clones. Thus, the principle underlying the present invention as claimed herein was fully confirmed. Particularly, it was proven that the present invention allows not only for successful delivery of several different genes of interest to a mammalian host cell using the baculovirus-based transduction system but also for successful expression of the delivered genes.
Analogously, co-transfection of a pool of eight different baculovirus clones each clone comprising another influenza virus gene or gene segment can likewise result in successful transcription and expression of the delivered genes and subsequent assembly of the expressed proteins to form virus particles.
REFERENCES
I. Enami, M., Luytjes, W., Krystal, M., and Palese, P.(1990). Introduction of site specific mutations into the genome of influenza virus. Proc. Natl Acad. Sci. USA. 87, 3802-3805. 2. Enami, M., and Palese, P.(1991). High-efficiency formation of influenza virus transfectants. J. Virol. 65, 2711-2713.
3. Luytjes, W., Krystals, M., Enami, M., Parvin, J. D., and Palese P. (1989). Amplification, expression, and packaging of a foreign gene by influenza virus. Cell. 59, 1107-1113. 4. Egorov, A., Brandt, S., Sereinig, S., Romanova, J., Ferko, B., Katinger, D., Grassauer, A., Alexandrova, G., Katinger, H., and Muster, T.(1998). Transfectant influenza virus with long deletions in the NSl protein grow efficiently in Vero cells. J. Virol, 72, 6437-6441.
5. Garcia-Sastre, A., Egorov, A., Matassov, D., Brandt, S., Levy, D. E., Durbin, J. E., Palese, P., and Muster, T. (1998). Influenza A virus lacking the NSl gene replicates in mterferon-deficient systems. Virology 252, 324-330.
6. Fodor, E., Devenish L., Engelhardt, O. G., Palese, P., Brownlee, G. G., and Garcia- Sastre, A.(1999). Rescue of influenza A virus from recombinant DNA. J. Virol. 73, 9679-9682. 7. Neuman, G., Watanabe, T., Ito, H., Watanabe, S., Goto, H., Goa, P., Huges, M., Perez, D.R., Donis, R., Hoffmann, E., Hobom, M., and Kawaoka, Y. (1999; Generation of influenza A viruses entirely from cloned cDNA. Proc. Natl. Acad. Sci.USA. 96, 9345-9350.
8. Shoji, H., Aizaki, H., Tani, H., Ishii, K., Chiba, T., Saito, I., Miyamura, T., and Mutsuura, T. (1997). Efficient gene transfer into various mammalian cells, including non-hepatic cells, by baculovirus vectors. J. Gen. Virol. 78, 2657-2664.
9. Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G. and Webster, R. G. (2000) A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. 97, 6108-6113. 10. Neuman, G., Zobel, A. and Hobom, G. (1994) RNA polymerase I mediates expression of influenza virual RNA molecules. Virology, 202, 477-479.
II. Neumann, G., Watanabe, T., and Kawaoka, Y. (2000). Plasmid-Driven Formation of Influenza Virus-Like Particles. J. Virol. 74:547-551

Claims

Claims We claim
1. A method for the rescue of attenuated and/or recombinant orthomyxovirus, comprising preparing a recombinant baculovirus by inserting at least one natural or modified gene or gene segment or a combination of a least one natural and at least one modified gene or gene segment, of orthomyxovirus into the genome of a baculovirus, delivering the resulting recombinant baculovirus genome to a mammalian host cell by transduction and incubating the transduced host cell to allow for expression of said one or more orthomyxovirus genes or gene segments.
2. The method of claim 1 , wherein the host cell is a VERO cell.
3. The method of claim 1 wherein all genes or gene segments of the attenuated and/or recombinant orthomyxovirus are transduced into the host cell by means of recombinant baculovirus.
4. The method of claim 3, wherein all of said genes or gene segments are inserted into a single baculovirus genome and are transduced all together into the host cell.
5. The method of claim 3, wherein said genes or gene segments are divided into portions and distributed to two or more baculovirus genomes and subsequently delivered to the host cell by co-transduction.
6. The method of claim 1, comprising delivery of at least one of said natural or modified orthomyxovirus genes or gene segments to the host cell by baculovirus transduction, and subsequent infection of the transduced host cell with a helper virus followed by selection for modified, i.e. reassorted, helper virus wherein said at least one transduced gene or gene segment replaces the corresponding gene or gene segment of the helper virus.
7. The method of claim 1, wherein said at least one modified gene or gene segment confers attenuation upon the rescued virus.
8. The method of claim 1, wherein the modified gene segment is a modified NS gene segment of influenza virus encoding an NSl protein of only 38 amino acids in length (ΔNS38).
9. The method of claim 1, wherein said at least one natural or modified gene or gene segment is flanked by restriction sites and wherein introduction and exchange of said gene or gene segment is carried out by cleavage of said restriction sites and subsequent direct ligation of said at least one gene or gene segment into the baculovirus genome.
10. Baculovirus genome that contains one or more uni- or bidirectional expression cassettes encoding at least one natural or modified gene or gene segment or a combination of a least one natural and at least one modified gene or gene segment, of an orthomyxovirus.
11. Baculovirus genome according to claim 10, wherein said at least one natural or modified gene or gene segment is from influenza A or B virus.
12. Baculovirus genome according to claim 10, wherein said at least one natural or modified gene or gene segment encodes viral mRNA or viral genomic RNA, or both viral mRNA and viral genomic RNA.
13. Baculovirus genome according to claim 10, wherein said at least one natural or modified gene or gene segment is flanked by restriction sites that allow for introduction and exchange of said gene or gene segment by cleavage of said restriction sites and subsequent direct ligation into the baculovirus genome.
14. Baculovirus genome according to claim 10, wherein said at least one natural or modified gene or gene segment comprises a modified NS gene segment of influenza virus encoding an NSl protein of only 38 amino acids in length (ΔNS38).
15. Baculovirus genome according to claim 10, wherein said at least one natural or modified gene or gene segment comprises a modified NS gene segment of influenza virus, a hemagglutinin (HA) and/or a neuraminidase (NA) gene segment of an epidemic influenza strain, and all remaining gene segments of said epidemic strain or of one or more other influenza wildtype or laboratory master strains.
16. Recombinant baculovirus comprising a modified genome as defined in claim 10.
17. A method for the manufacture of an orthomyxovirus vaccine, comprising transducing a baculovirus genome as defined in claim 10 into' a mammalian host cell, incubating the host cell to allow for expression of the transduced viral genes and for assembly of mature orthomyxovirus particles, separating and purifying the orthomyxovirus particles and combining them with a suitable carrier.
18. The method of claim 17, further comprising infecting the host cell with a helper virus after transduction of the baculovirus genome into the host cell.
19. The method of claim 17, further comprising processing the purified orthomyxovirus particles to obtain infectious virions.
20. The method of claim 17, for the manufacture of a live attenuated influenza vaccine.
PCT/EP2003/009375 2002-09-04 2003-08-23 Generation of recombinant influenza virus using baculovirus delivery vector WO2004022760A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003270099A AU2003270099A1 (en) 2002-09-04 2003-08-23 Generation of recombinant influenza virus using baculovirus delivery vector
EP03750434A EP1534845A1 (en) 2002-09-04 2003-08-23 Generation of recombinant influenza virus using baculovirus delivery vector

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40769502P 2002-09-04 2002-09-04
US60/407,695 2002-09-04

Publications (1)

Publication Number Publication Date
WO2004022760A1 true WO2004022760A1 (en) 2004-03-18

Family

ID=31978508

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/009375 WO2004022760A1 (en) 2002-09-04 2003-08-23 Generation of recombinant influenza virus using baculovirus delivery vector

Country Status (3)

Country Link
EP (1) EP1534845A1 (en)
AU (1) AU2003270099A1 (en)
WO (1) WO2004022760A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011012999A1 (en) * 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
WO2013014400A1 (en) * 2011-07-27 2013-01-31 Genethon Baculovirus system for the expression of a gene therapy vector
US8513006B2 (en) 2010-09-14 2013-08-20 University of Pittsburgh—of the Commonwealth System of Higher Education Tetravalent influenza vaccine and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOHANSSON B E: "Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 17, no. 15-16, 9 April 1999 (1999-04-09), pages 2073 - 2080, XP004165058, ISSN: 0264-410X *
POOMPUTSA K ET AL: "Generation of recombinant influenza virus using baculovirus delivery vector", JOURNAL OF VIROLOGICAL METHODS, vol. 110, pages 111 - 114, XP002264078 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017189179A (en) * 2009-07-31 2017-10-19 ノバルティス アーゲー Reverse genetics system
AU2010277310B2 (en) * 2009-07-31 2015-01-15 Seqirus UK Limited Reverse genetics systems
US10610584B2 (en) 2009-07-31 2020-04-07 Seqirus UK Limited Reverse genetics systems
WO2011012999A1 (en) * 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
CN104862335A (en) * 2009-07-31 2015-08-26 诺华股份有限公司 Reverse genetics systems
US9821052B2 (en) 2009-07-31 2017-11-21 Seqirus UK Limited Reverse genetics systems
JP2013500712A (en) * 2009-07-31 2013-01-10 ノバルティス アーゲー Reverse genetics
US8513006B2 (en) 2010-09-14 2013-08-20 University of Pittsburgh—of the Commonwealth System of Higher Education Tetravalent influenza vaccine and use thereof
US20140349374A1 (en) * 2011-07-27 2014-11-27 Genethon Baculovirus system for the expression of a gene therapy vector
FR2978456A1 (en) * 2011-07-27 2013-02-01 Genethon BACULOVIRAL SYSTEM FOR THE EXPRESSION OF A GENE THERAPEUTIC VECTOR
AU2012288681B2 (en) * 2011-07-27 2017-08-17 Genethon Baculovirus system for the expression of a gene therapy vector
US10017783B2 (en) * 2011-07-27 2018-07-10 Genethon Baculovirus system for the expression of a gene therapy vector
WO2013014400A1 (en) * 2011-07-27 2013-01-31 Genethon Baculovirus system for the expression of a gene therapy vector
US10767192B2 (en) 2011-07-27 2020-09-08 Genethon Baculovirus system for the expression of a gene therapy vector

Also Published As

Publication number Publication date
AU2003270099A1 (en) 2004-03-29
EP1534845A1 (en) 2005-06-01

Similar Documents

Publication Publication Date Title
JP5702321B2 (en) Influenza virus rescue
EP1194580B2 (en) In vitro reconstitution of segmented negative-strand rna viruses
JP5303603B2 (en) Multiple plasmid system for the production of influenza virus
JP5215561B2 (en) High-titer recombinant influenza virus for vaccines and gene therapy
JP5438065B2 (en) Virus encoding a mutated membrane protein
EP1748790B1 (en) Multi plasmid system for the production of influenza virus
US8043856B2 (en) Adenoviral vectors for influenza virus production
CA2526834A1 (en) Recombinant influenza vectors with a polii promoter and ribozymes
US20090017444A1 (en) Screening method for modulators of viral transcription or replication
US20220119839A1 (en) Recombinant influenza viruses and constructs and uses thereof
Machado et al. Expression of a foreign gene by stable recombinant influenza viruses harboring a dicistronic genomic segment with an internal promoter
WO2004022760A1 (en) Generation of recombinant influenza virus using baculovirus delivery vector
Poomputsa et al. Generation of recombinant influenza virus using baculovirus delivery vector
EP1200563B1 (en) Attenuated influenza virus useful as vaccine
JP2002513575A (en) Attenuated influenza virus
PT1194580E (en) In vitro reconstitution of segmented negative-strand rna viruses
Nakowitsch et al. Optimization of baculovirus transduction on freestyle TM 293 cells for the generation of influenza B/Lee/40
Class et al. Patent application title: RECOMBINANT INFLUENZA VIRUSES AND CONSTRUCTS AND USES THEREOF Inventors: Daniel R. Perez (Olney, MD, US) Daniel R. Perez Hongjun Chen (Hyattsville, MD, US) Hongjun Chen Yibin Cai (Hyattsville, MD, US) Yibin Cai Lindomar Jose Pena Lindomar Jose Pena (College Park, MD, US) Matthew Angel (Greenbelt, MD, US) Matthew Angel
Kawaoka et al. Recombinant influenza vectors with a PolII promoter and ribozymes for vaccines and gene therapy
Hayman et al. WedyH wadA A? ABA
MXPA05012700A (en) Recombinant influenza vectors with a polii promoter and ribozymes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003750434

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003750434

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003750434

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP